Key Takeaways:
- Nektar Therapeutics (NKTR, Financial) shares jump 22% after Jefferies upgrades rating.
- Analysts project an average target price of $4.92, indicating significant potential upside.
- GuruFocus estimates suggest a GF Value increase of 39.23% from the current stock price.
Nektar Therapeutics Surges on Analyst Upgrade
Nektar Therapeutics (NKTR) has seen its stock price make a notable leap, climbing by 22% as Jefferies upgraded its rating from hold to buy. Alongside this upgrade, Jefferies raised its price target to $2 per share, signaling renewed confidence in the company's prospects.
Wall Street Analysts' Projections
According to price targets set by six analysts over the next 12 months, the average predicted price for Nektar Therapeutics stands at $4.92. Forecasts range from a high of $7.00 to a low of $2.00. This average target suggests a substantial upside of 695.96% from the present trading price of $0.62. For more detailed projections, visit the Nektar Therapeutics (NKTR, Financial) Forecast page.
Brokerage Firm Recommendations
According to consensus from eight brokerage establishments, Nektar Therapeutics currently holds an average recommendation rating of 2.0, classified as "Outperform." This recommendation scale ranges from 1 to 5, where 1 denotes a Strong Buy and 5 indicates a Sell.
GuruFocus GF Value Analysis
GuruFocus has projected the GF Value for Nektar Therapeutics to reach $0.86 within the coming year, offering an upside potential of 39.23% from its current price of $0.6177. The GF Value represents GuruFocus's fair value estimate, incorporating historical multiples, past growth performance, and future business estimates. For a comprehensive overview, consult the Nektar Therapeutics (NKTR, Financial) Summary page.
